Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OIG counsel joins Alston & Bird

Executive Summary

Former HHS Office of Inspector General Senior Counsel Peggy Whitmore joined Alston & Bird's health care practice. Whitmore most recently served in the Industry Guidance Branch at OIG, where her work involved the anti-kickback statute and discounts for uninsured patients. The health care practice includes former Centers for Medicare & Medicaid Services Administrator Tom Scully and former CMS Senior Policy Advisor Tim Trysla (1"The Pink Sheet" April 18, 2005, In Brief)...

You may also be interested in...



CMS senior advisor joins Alston & Bird

Centers for Medicare & Medicaid Services Senior Policy Advisor Tim Trysla is joining Alston & Bird's health care practice. Trysla will be rejoining his previous boss, former CMS Administrator Tom Scully (1"The Pink Sheet" Dec. 22, 2004, p. 5)...

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel